Sentence examples for a rationale for evaluation from inspiring English sources

Although polymorphisms were not directly evaluated by Innocenti and colleagues, their clinical report suggested flavopiridol∶metabolite ratio as a possible predictor of diarrhea with flavopiridol treatment and provided a rationale for evaluation of a genetic link with UGT isoforms [31].

Our results thus provide a rationale for evaluation of combination therapy with ALK and MEK inhibitors in EML4 ALK-positive NSCLC patiEML4 ALK-positive iNSCLCtors alone show little effect.

Our results also provide a rationale for clinical evaluation of the combinations of bortezomib and oridonin (or other inhibitors of NF-κB1/2) or AD 198 (or other drugs targeting c-Myc) in the treatment of lymphoma and MM, especially in patients containing TRAF3 deletions or relevant mutations.

These data provide a rationale for further evaluation of the combination of Wee1 and Chk1/2 inhibitors in malignant melanoma.

The above observations would create a rationale for future evaluation of cabozantinib in earlier stages of prostate cancer, such as in the adjuvant setting for high-risk disease or hormone-sensitive disease.

In summary, our results support an increased anti-tumour effect of combined inhibition of Wee1 and Chk1/2 and provide a rationale for further evaluation of the kinases as therapeutic targets in human melanomas.

Relative dose escalation, increased biological effectiveness and oxygen independence of radiation effect therefore provide a rationale for the evaluation of particle therapy in the multi-modality treatment of advanced SCCHN.

As a rationale for the evaluation of losartan treatment, we first showed that patients with RDEB display increased TGF-β levels and activity in wounds, and in the circulation (Supplementary Fig S1) (Ng et al, 2012; Kuttner et al, 2013; Nystrom et al, 2013; Wang et al, 2013b; Odorisio et al, 2014).

In conclusion, our results provide a rationale for further clinical evaluation of darolutamide in enzalutamide-resistant CRPC, in particular in combination with circulating tumor DNA assays that detect AR mutants sensitive to darolutamide, in a precision oncology setting.

Our findings provide a rationale for the clinical evaluation of pacritinib in AML including patients resistant to FLT3-TKI therapy.

This preclinical data provides a rationale for a clinical evaluation of pacritinib in AML including patients resistant to FLT3-TKI therapy.